EyeAccess (190133662)

  https://cordis.europa.eu/project/id/190133662

  Horizon Europe (2021-2027)

  Direct Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in seconds

  EIC Accelerator Open 2021 (HORIZON-EIC-2021-ACCELERATOROPEN-01)

  glaucoma  ·  pharmaceutical drugs  ·  laser physics

  2022-01-01 Start Date (YY-MM-DD)

  2022-12-31 End Date (YY-MM-DD)

  € 6,589,750

  Description

Our novel laser technology - Direct Selective Laser Trabeculoplasty (DSLT) is an automated laser procedure for accessible primary treatment of glaucoma and ocular hypertension. Our Eagle™ device has the potential to revolutionize glaucoma care as it is non-contact, intuitive, and quick. The technology is ground-breaking, as the procedure doesn’t require expertise and involves simply pressing a button and delivering treatment in seconds. DSLT technology is poised to achieve widespread acceptance, as it is not limited to glaucoma specialists, or bound to glaucoma medication compliance. In addition, our technology is supported by promising First-in-Human clinical trial results as well as the expertise and guidance of key opinion leaders in the field of ophthalmology. EIC funding will support BELKIN Laser (re-branded recently as BELKIN Vision) in commercializing this sight-saving technology by establishing the commercial value chain, market launch, and scale-up.

  Complicit Organisations

1 Israeli organisation participates in EyeAccess.